# PeptideScanner evidence objects: Teduglutide

Every published version of the records placed with Teduglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/teduglutide.json. Selected public evidence only; not medical advice.

- Objects: 58
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00072839-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00072839

> PeptideScanner retained ClinicalTrials.gov record NCT00072839 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-25, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00072839-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00072839-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00072839-teduglutide-v1
- Content SHA-256: `6f01ef6ac6b88d2d69d016dc4a87d02ec655d1e176b060f287792a6b3f32bfab`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00072839 ([`ctg-observation-nct00072839-2021-05-25-35df58710634`](#source-ctg-observation-nct00072839-2021-05-25-35df58710634))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00072839 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-25, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00072839-2021-05-25-35df58710634`](#source-ctg-observation-nct00072839-2021-05-25-35df58710634))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00072839 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-25, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00072839-2021-05-25-35df58710634`](#source-ctg-observation-nct00072839-2021-05-25-35df58710634))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00072839-2021-05-25-35df58710634`](#source-ctg-observation-nct00072839-2021-05-25-35df58710634))

### Sources

<a id="source-ctg-observation-nct00072839-2021-05-25-35df58710634"></a>
- **ClinicalTrials.gov record NCT00072839 · retained source version 2021-05-25:35df58710634764db492a3d38daab34876b7b441a6e6beb13b586bcbe57a98f6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00072839) (`ctg-observation-nct00072839-2021-05-25-35df58710634`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00072839." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00072839-teduglutide-v1 SHA-256: 6f01ef6ac6b88d2d69d016dc4a87d02ec655d1e176b060f287792a6b3f32bfab.

---

<a id="clinicaltrials-gov-nct00081458-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00081458

> PeptideScanner retained ClinicalTrials.gov record NCT00081458 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00081458-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00081458-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00081458-teduglutide-v1
- Content SHA-256: `7f065131560a63b65d3c9091325569e60306980de3f1bdecf7b1654f02adaad4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00081458 ([`ctg-observation-nct00081458-2021-06-09-d01cea274c54`](#source-ctg-observation-nct00081458-2021-06-09-d01cea274c54))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00081458 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00081458-2021-06-09-d01cea274c54`](#source-ctg-observation-nct00081458-2021-06-09-d01cea274c54))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00081458 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00081458-2021-06-09-d01cea274c54`](#source-ctg-observation-nct00081458-2021-06-09-d01cea274c54))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00081458-2021-06-09-d01cea274c54`](#source-ctg-observation-nct00081458-2021-06-09-d01cea274c54))

### Sources

<a id="source-ctg-observation-nct00081458-2021-06-09-d01cea274c54"></a>
- **ClinicalTrials.gov record NCT00081458 · retained source version 2021-06-09:d01cea274c5480a6d6fe013a4572c0411b41c9a6dbec61f0c38c09f7df245a61** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00081458) (`ctg-observation-nct00081458-2021-06-09-d01cea274c54`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00081458." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00081458-teduglutide-v1 SHA-256: 7f065131560a63b65d3c9091325569e60306980de3f1bdecf7b1654f02adaad4.

---

<a id="clinicaltrials-gov-nct00172185-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00172185

> PeptideScanner retained ClinicalTrials.gov record NCT00172185 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00172185-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00172185-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00172185-teduglutide-v1
- Content SHA-256: `64c1fdc18f95402a26d7256505d4b38df8087e918e39d6a618db0cbc9f66b7ad`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00172185 ([`ctg-observation-nct00172185-2021-06-02-506679584052`](#source-ctg-observation-nct00172185-2021-06-02-506679584052))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00172185 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00172185-2021-06-02-506679584052`](#source-ctg-observation-nct00172185-2021-06-02-506679584052))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00172185 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00172185-2021-06-02-506679584052`](#source-ctg-observation-nct00172185-2021-06-02-506679584052))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00172185-2021-06-02-506679584052`](#source-ctg-observation-nct00172185-2021-06-02-506679584052))

### Sources

<a id="source-ctg-observation-nct00172185-2021-06-02-506679584052"></a>
- **ClinicalTrials.gov record NCT00172185 · retained source version 2021-06-02:5066795840520ac4bea5f9ebd4e7b1beea2808bb1c67e1b8ba948d035400fc00** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00172185) (`ctg-observation-nct00172185-2021-06-02-506679584052`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00172185." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00172185-teduglutide-v1 SHA-256: 64c1fdc18f95402a26d7256505d4b38df8087e918e39d6a618db0cbc9f66b7ad.

---

<a id="clinicaltrials-gov-nct00308438-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00308438

> PeptideScanner retained ClinicalTrials.gov record NCT00308438 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00308438-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00308438-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00308438-teduglutide-v1
- Content SHA-256: `bda6f77294e6052c7125649bb3d752d6d07349366cfc052aa686636a979c5c3f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00308438 ([`ctg-observation-nct00308438-2021-05-14-4076f7687ad2`](#source-ctg-observation-nct00308438-2021-05-14-4076f7687ad2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00308438 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00308438-2021-05-14-4076f7687ad2`](#source-ctg-observation-nct00308438-2021-05-14-4076f7687ad2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00308438 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00308438-2021-05-14-4076f7687ad2`](#source-ctg-observation-nct00308438-2021-05-14-4076f7687ad2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00308438-2021-05-14-4076f7687ad2`](#source-ctg-observation-nct00308438-2021-05-14-4076f7687ad2))

### Sources

<a id="source-ctg-observation-nct00308438-2021-05-14-4076f7687ad2"></a>
- **ClinicalTrials.gov record NCT00308438 · retained source version 2021-05-14:4076f7687ad2fb16a7fee4259037969e63ad767290f37a78d532825a8429317c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00308438) (`ctg-observation-nct00308438-2021-05-14-4076f7687ad2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00308438." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00308438-teduglutide-v1 SHA-256: bda6f77294e6052c7125649bb3d752d6d07349366cfc052aa686636a979c5c3f.

---

<a id="clinicaltrials-gov-nct00798967-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00798967

> PeptideScanner retained ClinicalTrials.gov record NCT00798967 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00798967-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00798967-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00798967-teduglutide-v1
- Content SHA-256: `690a438e5df5bb5ea1d56e5917bac67e17e5d01c59f95d8460eae3d955e9e535`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00798967 ([`ctg-observation-nct00798967-2021-06-03-8707839adf74`](#source-ctg-observation-nct00798967-2021-06-03-8707839adf74))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00798967 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00798967-2021-06-03-8707839adf74`](#source-ctg-observation-nct00798967-2021-06-03-8707839adf74))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00798967 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00798967-2021-06-03-8707839adf74`](#source-ctg-observation-nct00798967-2021-06-03-8707839adf74))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00798967-2021-06-03-8707839adf74`](#source-ctg-observation-nct00798967-2021-06-03-8707839adf74))

### Sources

<a id="source-ctg-observation-nct00798967-2021-06-03-8707839adf74"></a>
- **ClinicalTrials.gov record NCT00798967 · retained source version 2021-06-03:8707839adf74d306a2c0382b5b5620176e827832cca3cafe4f1f3257b335028b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00798967) (`ctg-observation-nct00798967-2021-06-03-8707839adf74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00798967." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00798967-teduglutide-v1 SHA-256: 690a438e5df5bb5ea1d56e5917bac67e17e5d01c59f95d8460eae3d955e9e535.

---

<a id="clinicaltrials-gov-nct00819468-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00819468

> PeptideScanner retained ClinicalTrials.gov record NCT00819468 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00819468-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00819468-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00819468-teduglutide-v1
- Content SHA-256: `41783f0c3bebf51d7e70fa9d77d63149ee890b908c26e870224082bce77c35d2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00819468 ([`ctg-observation-nct00819468-2021-05-14-f864b4d7109b`](#source-ctg-observation-nct00819468-2021-05-14-f864b4d7109b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00819468 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00819468-2021-05-14-f864b4d7109b`](#source-ctg-observation-nct00819468-2021-05-14-f864b4d7109b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00819468 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00819468-2021-05-14-f864b4d7109b`](#source-ctg-observation-nct00819468-2021-05-14-f864b4d7109b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00819468-2021-05-14-f864b4d7109b`](#source-ctg-observation-nct00819468-2021-05-14-f864b4d7109b))

### Sources

<a id="source-ctg-observation-nct00819468-2021-05-14-f864b4d7109b"></a>
- **ClinicalTrials.gov record NCT00819468 · retained source version 2021-05-14:f864b4d7109b844cf62776611e9d635879d561fef85f4a97416ffee4d260876f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00819468) (`ctg-observation-nct00819468-2021-05-14-f864b4d7109b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00819468." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00819468-teduglutide-v1 SHA-256: 41783f0c3bebf51d7e70fa9d77d63149ee890b908c26e870224082bce77c35d2.

---

<a id="clinicaltrials-gov-nct00930644-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT00930644

> PeptideScanner retained ClinicalTrials.gov record NCT00930644 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct00930644-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00930644-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00930644-teduglutide-v1
- Content SHA-256: `d8dea2d90ba6ff0345396dbfd9b0c9a98f5f8fd4b4266464fb16c9783316ebf9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00930644 ([`ctg-observation-nct00930644-2021-06-11-8404755d4c66`](#source-ctg-observation-nct00930644-2021-06-11-8404755d4c66))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00930644 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00930644-2021-06-11-8404755d4c66`](#source-ctg-observation-nct00930644-2021-06-11-8404755d4c66))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00930644 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct00930644-2021-06-11-8404755d4c66`](#source-ctg-observation-nct00930644-2021-06-11-8404755d4c66))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00930644-2021-06-11-8404755d4c66`](#source-ctg-observation-nct00930644-2021-06-11-8404755d4c66))

### Sources

<a id="source-ctg-observation-nct00930644-2021-06-11-8404755d4c66"></a>
- **ClinicalTrials.gov record NCT00930644 · retained source version 2021-06-11:8404755d4c666f8eac865dc4e3e214542ad04ca03b7e0798a03f3c42f7ce7f1e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00930644) (`ctg-observation-nct00930644-2021-06-11-8404755d4c66`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00930644." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct00930644-teduglutide-v1 SHA-256: d8dea2d90ba6ff0345396dbfd9b0c9a98f5f8fd4b4266464fb16c9783316ebf9.

---

<a id="clinicaltrials-gov-nct01028768-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT01028768

> PeptideScanner retained ClinicalTrials.gov record NCT01028768 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct01028768-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-05-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01028768-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01028768-teduglutide-v1
- Content SHA-256: `71f5774038f51708d966cc397e5021899509b59ff818991f2788dabf9732227f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01028768 ([`ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8`](#source-ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01028768 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8`](#source-ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01028768 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8`](#source-ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8`](#source-ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8))

### Sources

<a id="source-ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8"></a>
- **ClinicalTrials.gov record NCT01028768 · retained source version 2012-05-07:4ebe3c53c9b8ed9a5c90a8590ced28b0dde7602a470ff83a2a2d25a66a3804cb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01028768) (`ctg-observation-nct01028768-2012-05-07-4ebe3c53c9b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01028768." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01028768-teduglutide-v1 SHA-256: 71f5774038f51708d966cc397e5021899509b59ff818991f2788dabf9732227f.

---

<a id="clinicaltrials-gov-nct01028924-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT01028924

> PeptideScanner retained ClinicalTrials.gov record NCT01028924 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct01028924-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-05-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01028924-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01028924-teduglutide-v1
- Content SHA-256: `4d91e421dc6acfaea713dd37e92695c39389f9e896ff039b487f31646a84813c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01028924 ([`ctg-observation-nct01028924-2012-05-07-87b901922bd2`](#source-ctg-observation-nct01028924-2012-05-07-87b901922bd2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01028924 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01028924-2012-05-07-87b901922bd2`](#source-ctg-observation-nct01028924-2012-05-07-87b901922bd2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01028924 at 2026-11-15T21:55:23.600Z. Its registry update date was 2012-05-07, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01028924-2012-05-07-87b901922bd2`](#source-ctg-observation-nct01028924-2012-05-07-87b901922bd2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01028924-2012-05-07-87b901922bd2`](#source-ctg-observation-nct01028924-2012-05-07-87b901922bd2))

### Sources

<a id="source-ctg-observation-nct01028924-2012-05-07-87b901922bd2"></a>
- **ClinicalTrials.gov record NCT01028924 · retained source version 2012-05-07:87b901922bd2812c86136beca2ad710b2733377bcc3dc4e4b56202967ddea96a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01028924) (`ctg-observation-nct01028924-2012-05-07-87b901922bd2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01028924." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01028924-teduglutide-v1 SHA-256: 4d91e421dc6acfaea713dd37e92695c39389f9e896ff039b487f31646a84813c.

---

<a id="clinicaltrials-gov-nct01209351-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT01209351

> PeptideScanner retained ClinicalTrials.gov record NCT01209351 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-04, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct01209351-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01209351-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01209351-teduglutide-v1
- Content SHA-256: `7e9385cf1b4b848f382b83c4625490bfea1356189d2db604e161dde0f9ae3e45`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01209351 ([`ctg-observation-nct01209351-2021-06-04-8bd833395fac`](#source-ctg-observation-nct01209351-2021-06-04-8bd833395fac))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01209351 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-04, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01209351-2021-06-04-8bd833395fac`](#source-ctg-observation-nct01209351-2021-06-04-8bd833395fac))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01209351 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-04, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01209351-2021-06-04-8bd833395fac`](#source-ctg-observation-nct01209351-2021-06-04-8bd833395fac))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01209351-2021-06-04-8bd833395fac`](#source-ctg-observation-nct01209351-2021-06-04-8bd833395fac))

### Sources

<a id="source-ctg-observation-nct01209351-2021-06-04-8bd833395fac"></a>
- **ClinicalTrials.gov record NCT01209351 · retained source version 2021-06-04:8bd833395fac4d02e073896dca895f3c59fd078da348a68cd8dc2d65eda824c8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01209351) (`ctg-observation-nct01209351-2021-06-04-8bd833395fac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01209351." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01209351-teduglutide-v1 SHA-256: 7e9385cf1b4b848f382b83c4625490bfea1356189d2db604e161dde0f9ae3e45.

---

<a id="clinicaltrials-gov-nct01560403-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT01560403

> PeptideScanner retained ClinicalTrials.gov record NCT01560403 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct01560403-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01560403-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01560403-teduglutide-v1
- Content SHA-256: `e0d87be3bc655f2d7a41fa763dde8da5dac5a5fc75ad8ceb2fc2c67b8e357f72`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01560403 ([`ctg-observation-nct01560403-2021-06-10-3c43ab18ba07`](#source-ctg-observation-nct01560403-2021-06-10-3c43ab18ba07))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01560403 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01560403-2021-06-10-3c43ab18ba07`](#source-ctg-observation-nct01560403-2021-06-10-3c43ab18ba07))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01560403 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01560403-2021-06-10-3c43ab18ba07`](#source-ctg-observation-nct01560403-2021-06-10-3c43ab18ba07))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01560403-2021-06-10-3c43ab18ba07`](#source-ctg-observation-nct01560403-2021-06-10-3c43ab18ba07))

### Sources

<a id="source-ctg-observation-nct01560403-2021-06-10-3c43ab18ba07"></a>
- **ClinicalTrials.gov record NCT01560403 · retained source version 2021-06-10:3c43ab18ba07a852003314c14509890af281492872ea8e1d8c3f2223b44535e8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01560403) (`ctg-observation-nct01560403-2021-06-10-3c43ab18ba07`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01560403." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01560403-teduglutide-v1 SHA-256: e0d87be3bc655f2d7a41fa763dde8da5dac5a5fc75ad8ceb2fc2c67b8e357f72.

---

<a id="clinicaltrials-gov-nct01952080-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT01952080

> PeptideScanner retained ClinicalTrials.gov record NCT01952080 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct01952080-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01952080-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01952080-teduglutide-v1
- Content SHA-256: `fb4c0a9902a3b91ccffbb5a12391d6c7a4f88d7c54308ae1b86f8fd5f36a4e9b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01952080 ([`ctg-observation-nct01952080-2021-06-09-0bb43d3230f6`](#source-ctg-observation-nct01952080-2021-06-09-0bb43d3230f6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01952080 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01952080-2021-06-09-0bb43d3230f6`](#source-ctg-observation-nct01952080-2021-06-09-0bb43d3230f6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01952080 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct01952080-2021-06-09-0bb43d3230f6`](#source-ctg-observation-nct01952080-2021-06-09-0bb43d3230f6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01952080-2021-06-09-0bb43d3230f6`](#source-ctg-observation-nct01952080-2021-06-09-0bb43d3230f6))

### Sources

<a id="source-ctg-observation-nct01952080-2021-06-09-0bb43d3230f6"></a>
- **ClinicalTrials.gov record NCT01952080 · retained source version 2021-06-09:0bb43d3230f6a0b0c85f21e270fdede1c08b9858abab015afd26f45d6f6a225a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01952080) (`ctg-observation-nct01952080-2021-06-09-0bb43d3230f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01952080." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct01952080-teduglutide-v1 SHA-256: fb4c0a9902a3b91ccffbb5a12391d6c7a4f88d7c54308ae1b86f8fd5f36a4e9b.

---

<a id="clinicaltrials-gov-nct02099084-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT02099084

> PeptideScanner retained ClinicalTrials.gov record NCT02099084 at 2026-11-15T21:55:23.600Z. Its registry update date was 2016-02-22, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct02099084-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-02-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02099084-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02099084-teduglutide-v1
- Content SHA-256: `96657d5c5bd2cb2f93461fdc774ebe81552596b1c626e773ac532695b3f0d3c3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02099084 ([`ctg-observation-nct02099084-2016-02-22-755a7293304c`](#source-ctg-observation-nct02099084-2016-02-22-755a7293304c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02099084 at 2026-11-15T21:55:23.600Z. Its registry update date was 2016-02-22, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02099084-2016-02-22-755a7293304c`](#source-ctg-observation-nct02099084-2016-02-22-755a7293304c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02099084 at 2026-11-15T21:55:23.600Z. Its registry update date was 2016-02-22, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02099084-2016-02-22-755a7293304c`](#source-ctg-observation-nct02099084-2016-02-22-755a7293304c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02099084-2016-02-22-755a7293304c`](#source-ctg-observation-nct02099084-2016-02-22-755a7293304c))

### Sources

<a id="source-ctg-observation-nct02099084-2016-02-22-755a7293304c"></a>
- **ClinicalTrials.gov record NCT02099084 · retained source version 2016-02-22:755a7293304c8a6cde5443d233ccdaa6a2d09aa06ab98332d3ff98efd20d7c65** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02099084) (`ctg-observation-nct02099084-2016-02-22-755a7293304c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02099084." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02099084-teduglutide-v1 SHA-256: 96657d5c5bd2cb2f93461fdc774ebe81552596b1c626e773ac532695b3f0d3c3.

---

<a id="clinicaltrials-gov-nct02340819-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT02340819

> PeptideScanner retained ClinicalTrials.gov record NCT02340819 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct02340819-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02340819-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02340819-teduglutide-v1
- Content SHA-256: `1f59c0c2e3eb2f964be4568da5f25c04928f4d2b8f0ed0ea95d937048d64af12`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02340819 ([`ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad`](#source-ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02340819 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad`](#source-ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02340819 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad`](#source-ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad`](#source-ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad))

### Sources

<a id="source-ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad"></a>
- **ClinicalTrials.gov record NCT02340819 · retained source version 2021-06-09:02a0bd1e4bad093e2e749ee3d69b3bc3e940e623ce248e0c8c246a18f3be58a6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02340819) (`ctg-observation-nct02340819-2021-06-09-02a0bd1e4bad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02340819." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02340819-teduglutide-v1 SHA-256: 1f59c0c2e3eb2f964be4568da5f25c04928f4d2b8f0ed0ea95d937048d64af12.

---

<a id="clinicaltrials-gov-nct02431325-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT02431325

> PeptideScanner retained ClinicalTrials.gov record NCT02431325 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-06-12, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct02431325-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-06-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02431325-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02431325-teduglutide-v1
- Content SHA-256: `5975032f851f42737590650c64c4c08b0b8f7e29dda9f9d49f0e428d6bb4cb17`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02431325 ([`ctg-observation-nct02431325-2023-06-12-0682e1e45071`](#source-ctg-observation-nct02431325-2023-06-12-0682e1e45071))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02431325 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-06-12, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02431325-2023-06-12-0682e1e45071`](#source-ctg-observation-nct02431325-2023-06-12-0682e1e45071))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02431325 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-06-12, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02431325-2023-06-12-0682e1e45071`](#source-ctg-observation-nct02431325-2023-06-12-0682e1e45071))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02431325-2023-06-12-0682e1e45071`](#source-ctg-observation-nct02431325-2023-06-12-0682e1e45071))

### Sources

<a id="source-ctg-observation-nct02431325-2023-06-12-0682e1e45071"></a>
- **ClinicalTrials.gov record NCT02431325 · retained source version 2023-06-12:0682e1e45071135b8fde843f02ad4d135f53006b0ebbba083aa9ae9047ada50a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02431325) (`ctg-observation-nct02431325-2023-06-12-0682e1e45071`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02431325." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02431325-teduglutide-v1 SHA-256: 5975032f851f42737590650c64c4c08b0b8f7e29dda9f9d49f0e428d6bb4cb17.

---

<a id="clinicaltrials-gov-nct02889393-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT02889393

> PeptideScanner retained ClinicalTrials.gov record NCT02889393 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-10-06, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct02889393-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02889393-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02889393-teduglutide-v1
- Content SHA-256: `7a5d91c76f808a62ae4a78df01c01c33297e2c171c083b6b3ba4e2fd35cc938c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02889393 ([`ctg-observation-nct02889393-2021-10-06-2a1db321c86e`](#source-ctg-observation-nct02889393-2021-10-06-2a1db321c86e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02889393 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-10-06, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02889393-2021-10-06-2a1db321c86e`](#source-ctg-observation-nct02889393-2021-10-06-2a1db321c86e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02889393 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-10-06, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02889393-2021-10-06-2a1db321c86e`](#source-ctg-observation-nct02889393-2021-10-06-2a1db321c86e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02889393-2021-10-06-2a1db321c86e`](#source-ctg-observation-nct02889393-2021-10-06-2a1db321c86e))

### Sources

<a id="source-ctg-observation-nct02889393-2021-10-06-2a1db321c86e"></a>
- **ClinicalTrials.gov record NCT02889393 · retained source version 2021-10-06:2a1db321c86efb5d97955fcc329a0d0ad9f7894c4dbcee79ecbe57aa0e60c6cd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02889393) (`ctg-observation-nct02889393-2021-10-06-2a1db321c86e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02889393." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02889393-teduglutide-v1 SHA-256: 7a5d91c76f808a62ae4a78df01c01c33297e2c171c083b6b3ba4e2fd35cc938c.

---

<a id="clinicaltrials-gov-nct02949362-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT02949362

> PeptideScanner retained ClinicalTrials.gov record NCT02949362 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-03-19, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct02949362-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02949362-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02949362-teduglutide-v1
- Content SHA-256: `096f39f2df8ecf42c6b11b27586529a660439d36291062423bb9ca85721f1e1f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02949362 ([`ctg-observation-nct02949362-2025-03-19-c89733d1db70`](#source-ctg-observation-nct02949362-2025-03-19-c89733d1db70))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02949362 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-03-19, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02949362-2025-03-19-c89733d1db70`](#source-ctg-observation-nct02949362-2025-03-19-c89733d1db70))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02949362 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-03-19, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02949362-2025-03-19-c89733d1db70`](#source-ctg-observation-nct02949362-2025-03-19-c89733d1db70))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02949362-2025-03-19-c89733d1db70`](#source-ctg-observation-nct02949362-2025-03-19-c89733d1db70))

### Sources

<a id="source-ctg-observation-nct02949362-2025-03-19-c89733d1db70"></a>
- **ClinicalTrials.gov record NCT02949362 · retained source version 2025-03-19:c89733d1db704c950549b5cbcca155ac255939a30a9ab901ca65b878b7bf3e91** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02949362) (`ctg-observation-nct02949362-2025-03-19-c89733d1db70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02949362." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02949362-teduglutide-v1 SHA-256: 096f39f2df8ecf42c6b11b27586529a660439d36291062423bb9ca85721f1e1f.

---

<a id="clinicaltrials-gov-nct02980666-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT02980666

> PeptideScanner retained ClinicalTrials.gov record NCT02980666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-02-02, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct02980666-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-02-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02980666-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02980666-teduglutide-v1
- Content SHA-256: `e1e7ae048317ecc44905f2078a131b20f6aba101cc0ea07a9845a244280013f7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02980666 ([`ctg-observation-nct02980666-2022-02-02-0fdef821067c`](#source-ctg-observation-nct02980666-2022-02-02-0fdef821067c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02980666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-02-02, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02980666-2022-02-02-0fdef821067c`](#source-ctg-observation-nct02980666-2022-02-02-0fdef821067c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02980666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-02-02, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct02980666-2022-02-02-0fdef821067c`](#source-ctg-observation-nct02980666-2022-02-02-0fdef821067c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02980666-2022-02-02-0fdef821067c`](#source-ctg-observation-nct02980666-2022-02-02-0fdef821067c))

### Sources

<a id="source-ctg-observation-nct02980666-2022-02-02-0fdef821067c"></a>
- **ClinicalTrials.gov record NCT02980666 · retained source version 2022-02-02:0fdef821067c718394d654359fc4f64394e1dfd5f25130d7c295a375d86c880a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02980666) (`ctg-observation-nct02980666-2022-02-02-0fdef821067c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02980666." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct02980666-teduglutide-v1 SHA-256: e1e7ae048317ecc44905f2078a131b20f6aba101cc0ea07a9845a244280013f7.

---

<a id="clinicaltrials-gov-nct03268811-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03268811

> PeptideScanner retained ClinicalTrials.gov record NCT03268811 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-24, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03268811-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03268811-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03268811-teduglutide-v1
- Content SHA-256: `58c5a24959b6bbbdcc10e5ead5188964168b346efc2efbc2f4a80c59c25578d1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03268811 ([`ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4`](#source-ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03268811 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-24, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4`](#source-ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03268811 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-24, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4`](#source-ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4`](#source-ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4))

### Sources

<a id="source-ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4"></a>
- **ClinicalTrials.gov record NCT03268811 · retained source version 2022-05-24:b3976fdaf3a4669faa5d59f590274204ccc02572defa697ba0ed5828f287496e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03268811) (`ctg-observation-nct03268811-2022-05-24-b3976fdaf3a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03268811." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03268811-teduglutide-v1 SHA-256: 58c5a24959b6bbbdcc10e5ead5188964168b346efc2efbc2f4a80c59c25578d1.

---

<a id="clinicaltrials-gov-nct03422666-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03422666

> PeptideScanner retained ClinicalTrials.gov record NCT03422666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-06-14, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03422666-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03422666-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03422666-teduglutide-v1
- Content SHA-256: `3d8c92ca7671c16c754d6d28d33bdaa02e6301822f38efd6c922b81cce68c37c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03422666 ([`ctg-observation-nct03422666-2022-06-14-a234d0df16e4`](#source-ctg-observation-nct03422666-2022-06-14-a234d0df16e4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03422666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-06-14, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03422666-2022-06-14-a234d0df16e4`](#source-ctg-observation-nct03422666-2022-06-14-a234d0df16e4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03422666 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-06-14, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03422666-2022-06-14-a234d0df16e4`](#source-ctg-observation-nct03422666-2022-06-14-a234d0df16e4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03422666-2022-06-14-a234d0df16e4`](#source-ctg-observation-nct03422666-2022-06-14-a234d0df16e4))

### Sources

<a id="source-ctg-observation-nct03422666-2022-06-14-a234d0df16e4"></a>
- **ClinicalTrials.gov record NCT03422666 · retained source version 2022-06-14:a234d0df16e41abdf29f2677ac5e50f7bbca5623812d5c7cdec4aba529f8539f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03422666) (`ctg-observation-nct03422666-2022-06-14-a234d0df16e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03422666." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03422666-teduglutide-v1 SHA-256: 3d8c92ca7671c16c754d6d28d33bdaa02e6301822f38efd6c922b81cce68c37c.

---

<a id="clinicaltrials-gov-nct03442972-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03442972

> PeptideScanner retained ClinicalTrials.gov record NCT03442972 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03442972-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03442972-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03442972-teduglutide-v1
- Content SHA-256: `48e37c176c354baa57696afd49987a5d34a2f4631fff2cc8079a5d5226b04cf8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03442972 ([`ctg-observation-nct03442972-2022-05-25-028583461e58`](#source-ctg-observation-nct03442972-2022-05-25-028583461e58))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03442972 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03442972-2022-05-25-028583461e58`](#source-ctg-observation-nct03442972-2022-05-25-028583461e58))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03442972 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03442972-2022-05-25-028583461e58`](#source-ctg-observation-nct03442972-2022-05-25-028583461e58))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03442972-2022-05-25-028583461e58`](#source-ctg-observation-nct03442972-2022-05-25-028583461e58))

### Sources

<a id="source-ctg-observation-nct03442972-2022-05-25-028583461e58"></a>
- **ClinicalTrials.gov record NCT03442972 · retained source version 2022-05-25:028583461e589381d338a04911b747dbe3c6d266623a2320ad93943812663d7d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03442972) (`ctg-observation-nct03442972-2022-05-25-028583461e58`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03442972." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03442972-teduglutide-v1 SHA-256: 48e37c176c354baa57696afd49987a5d34a2f4631fff2cc8079a5d5226b04cf8.

---

<a id="clinicaltrials-gov-nct03562130-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03562130

> PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03562130-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03562130-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03562130-teduglutide-v1
- Content SHA-256: `a2302bf849975697cf614495c43912315181ae2c81c12b142266fc4a50617d85`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03562130 ([`ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36`](#source-ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36`](#source-ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36`](#source-ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36`](#source-ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36))

### Sources

<a id="source-ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36"></a>
- **ClinicalTrials.gov record NCT03562130 · retained source version 2025-09-11:7a7ab26b4a3647a97c210d3b0ffa527a9b4da4e3b8ae3636c2c8266d4338201a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03562130) (`ctg-observation-nct03562130-2025-09-11-7a7ab26b4a36`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03562130." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03562130-teduglutide-v1 SHA-256: a2302bf849975697cf614495c43912315181ae2c81c12b142266fc4a50617d85.

---

<a id="clinicaltrials-gov-nct03571516-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03571516

> PeptideScanner retained ClinicalTrials.gov record NCT03571516 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03571516-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03571516-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03571516-teduglutide-v1
- Content SHA-256: `9d9a3a3394a8b67e5341c9d095b1290dacafcf869935c4bef0c8d6243b7fada2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03571516 ([`ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf`](#source-ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03571516 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf`](#source-ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03571516 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf`](#source-ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf`](#source-ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf))

### Sources

<a id="source-ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf"></a>
- **ClinicalTrials.gov record NCT03571516 · retained source version 2021-05-11:df0dd7e53cdf592fbe2eecfa454b188422fa207fc8fafe3a00276d080287ca59** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03571516) (`ctg-observation-nct03571516-2021-05-11-df0dd7e53cdf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03571516." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03571516-teduglutide-v1 SHA-256: 9d9a3a3394a8b67e5341c9d095b1290dacafcf869935c4bef0c8d6243b7fada2.

---

<a id="clinicaltrials-gov-nct03596164-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03596164

> PeptideScanner retained ClinicalTrials.gov record NCT03596164 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-03-15, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03596164-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-03-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03596164-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03596164-teduglutide-v1
- Content SHA-256: `ee2dd00e13ad8f60d0d3f997faee968df24a57427d0962a687474a2d2a8bef99`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03596164 ([`ctg-observation-nct03596164-2023-03-15-98ac841841b6`](#source-ctg-observation-nct03596164-2023-03-15-98ac841841b6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03596164 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-03-15, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03596164-2023-03-15-98ac841841b6`](#source-ctg-observation-nct03596164-2023-03-15-98ac841841b6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03596164 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-03-15, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03596164-2023-03-15-98ac841841b6`](#source-ctg-observation-nct03596164-2023-03-15-98ac841841b6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03596164-2023-03-15-98ac841841b6`](#source-ctg-observation-nct03596164-2023-03-15-98ac841841b6))

### Sources

<a id="source-ctg-observation-nct03596164-2023-03-15-98ac841841b6"></a>
- **ClinicalTrials.gov record NCT03596164 · retained source version 2023-03-15:98ac841841b6079302fdabcc25e9cdc63d6a20b11f6a7fc9c772214d3c2c569d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03596164) (`ctg-observation-nct03596164-2023-03-15-98ac841841b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03596164." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03596164-teduglutide-v1 SHA-256: ee2dd00e13ad8f60d0d3f997faee968df24a57427d0962a687474a2d2a8bef99.

---

<a id="clinicaltrials-gov-nct03663582-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03663582

> PeptideScanner retained ClinicalTrials.gov record NCT03663582 at 2026-11-15T21:55:23.600Z. Its registry update date was 2020-08-04, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03663582-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-08-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03663582-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03663582-teduglutide-v1
- Content SHA-256: `74209977de200ebcf742536f59d10dfd4ba06c7ead30da40fc409e604644cb28`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03663582 ([`ctg-observation-nct03663582-2020-08-04-9f2f423de8ab`](#source-ctg-observation-nct03663582-2020-08-04-9f2f423de8ab))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03663582 at 2026-11-15T21:55:23.600Z. Its registry update date was 2020-08-04, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03663582-2020-08-04-9f2f423de8ab`](#source-ctg-observation-nct03663582-2020-08-04-9f2f423de8ab))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03663582 at 2026-11-15T21:55:23.600Z. Its registry update date was 2020-08-04, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03663582-2020-08-04-9f2f423de8ab`](#source-ctg-observation-nct03663582-2020-08-04-9f2f423de8ab))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03663582-2020-08-04-9f2f423de8ab`](#source-ctg-observation-nct03663582-2020-08-04-9f2f423de8ab))

### Sources

<a id="source-ctg-observation-nct03663582-2020-08-04-9f2f423de8ab"></a>
- **ClinicalTrials.gov record NCT03663582 · retained source version 2020-08-04:9f2f423de8abb3b0f49f3e84aded61eaf636314dbe69d24582b57fc5356cf4e2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03663582) (`ctg-observation-nct03663582-2020-08-04-9f2f423de8ab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03663582." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03663582-teduglutide-v1 SHA-256: 74209977de200ebcf742536f59d10dfd4ba06c7ead30da40fc409e604644cb28.

---

<a id="clinicaltrials-gov-nct03716115-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT03716115

> PeptideScanner retained ClinicalTrials.gov record NCT03716115 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-09-27, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct03716115-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-09-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03716115-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03716115-teduglutide-v1
- Content SHA-256: `4733db14a523980b1b5d2b3ef97eae4982494372b89f022cde5d0f2b81ff1be9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03716115 ([`ctg-observation-nct03716115-2021-09-27-49dc9b428d23`](#source-ctg-observation-nct03716115-2021-09-27-49dc9b428d23))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03716115 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-09-27, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03716115-2021-09-27-49dc9b428d23`](#source-ctg-observation-nct03716115-2021-09-27-49dc9b428d23))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03716115 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-09-27, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct03716115-2021-09-27-49dc9b428d23`](#source-ctg-observation-nct03716115-2021-09-27-49dc9b428d23))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03716115-2021-09-27-49dc9b428d23`](#source-ctg-observation-nct03716115-2021-09-27-49dc9b428d23))

### Sources

<a id="source-ctg-observation-nct03716115-2021-09-27-49dc9b428d23"></a>
- **ClinicalTrials.gov record NCT03716115 · retained source version 2021-09-27:49dc9b428d2362e772e9a70dd805ea3eec79de625290611fa63740a29e6afde8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03716115) (`ctg-observation-nct03716115-2021-09-27-49dc9b428d23`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03716115." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct03716115-teduglutide-v1 SHA-256: 4733db14a523980b1b5d2b3ef97eae4982494372b89f022cde5d0f2b81ff1be9.

---

<a id="clinicaltrials-gov-nct04290429-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT04290429

> PeptideScanner retained ClinicalTrials.gov record NCT04290429 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-11-29, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct04290429-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-11-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04290429-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct04290429-teduglutide-v1
- Content SHA-256: `31c46f8fadc267a1cd9ea9c16df12fe8aa846607eafd09a1fe49a11243d54421`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04290429 ([`ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4`](#source-ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04290429 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-11-29, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4`](#source-ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04290429 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-11-29, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4`](#source-ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4`](#source-ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4))

### Sources

<a id="source-ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4"></a>
- **ClinicalTrials.gov record NCT04290429 · retained source version 2023-11-29:39dd8d20a3c474be17c17ee228283782e595fecaaaba474a15788052fbf5fc9a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04290429) (`ctg-observation-nct04290429-2023-11-29-39dd8d20a3c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04290429." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct04290429-teduglutide-v1 SHA-256: 31c46f8fadc267a1cd9ea9c16df12fe8aa846607eafd09a1fe49a11243d54421.

---

<a id="clinicaltrials-gov-nct04465396-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT04465396

> PeptideScanner retained ClinicalTrials.gov record NCT04465396 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-10-04, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct04465396-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-10-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04465396-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct04465396-teduglutide-v1
- Content SHA-256: `b2c8f4b1f3c1de41cf918df79d0f8fa21bf79360f3fb50be47fd0ddb0316ab28`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04465396 ([`ctg-observation-nct04465396-2022-10-04-a258625004f5`](#source-ctg-observation-nct04465396-2022-10-04-a258625004f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04465396 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-10-04, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct04465396-2022-10-04-a258625004f5`](#source-ctg-observation-nct04465396-2022-10-04-a258625004f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04465396 at 2026-11-15T21:55:23.600Z. Its registry update date was 2022-10-04, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct04465396-2022-10-04-a258625004f5`](#source-ctg-observation-nct04465396-2022-10-04-a258625004f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04465396-2022-10-04-a258625004f5`](#source-ctg-observation-nct04465396-2022-10-04-a258625004f5))

### Sources

<a id="source-ctg-observation-nct04465396-2022-10-04-a258625004f5"></a>
- **ClinicalTrials.gov record NCT04465396 · retained source version 2022-10-04:a258625004f513c08ccc1301c6302de5702b570f4a2a5a612c01607632fcee4e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04465396) (`ctg-observation-nct04465396-2022-10-04-a258625004f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04465396." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct04465396-teduglutide-v1 SHA-256: b2c8f4b1f3c1de41cf918df79d0f8fa21bf79360f3fb50be47fd0ddb0316ab28.

---

<a id="clinicaltrials-gov-nct05027308-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT05027308

> PeptideScanner retained ClinicalTrials.gov record NCT05027308 at 2026-11-15T21:55:23.600Z. Its registry update date was 2024-05-16, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct05027308-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-05-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05027308-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct05027308-teduglutide-v1
- Content SHA-256: `10ce69bfceb5e965acd1f84168f77f7272b65340ae484054c0c155a179e20bfb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05027308 ([`ctg-observation-nct05027308-2024-05-16-2f3a5921d73c`](#source-ctg-observation-nct05027308-2024-05-16-2f3a5921d73c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05027308 at 2026-11-15T21:55:23.600Z. Its registry update date was 2024-05-16, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct05027308-2024-05-16-2f3a5921d73c`](#source-ctg-observation-nct05027308-2024-05-16-2f3a5921d73c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05027308 at 2026-11-15T21:55:23.600Z. Its registry update date was 2024-05-16, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct05027308-2024-05-16-2f3a5921d73c`](#source-ctg-observation-nct05027308-2024-05-16-2f3a5921d73c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05027308-2024-05-16-2f3a5921d73c`](#source-ctg-observation-nct05027308-2024-05-16-2f3a5921d73c))

### Sources

<a id="source-ctg-observation-nct05027308-2024-05-16-2f3a5921d73c"></a>
- **ClinicalTrials.gov record NCT05027308 · retained source version 2024-05-16:2f3a5921d73c7e4c0566efc9180f888da030af36770f3b1468150c2d4397224e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05027308) (`ctg-observation-nct05027308-2024-05-16-2f3a5921d73c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05027308." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct05027308-teduglutide-v1 SHA-256: 10ce69bfceb5e965acd1f84168f77f7272b65340ae484054c0c155a179e20bfb.

---

<a id="clinicaltrials-gov-nct06973304-teduglutide-v1"></a>

## ClinicalTrials.gov record NCT06973304

> PeptideScanner retained ClinicalTrials.gov record NCT06973304 at 2026-11-15T21:55:23.600Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was teduglutide.

- Evidence object: `story:clinicaltrials-gov-nct06973304-teduglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06973304-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct06973304-teduglutide-v1
- Content SHA-256: `fea3feab3aec8b9642284d702c5749b40bffe4f08ca0f556f7e86abc8afc3baa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06973304 ([`ctg-observation-nct06973304-2026-09-08-9eb77aabedd9`](#source-ctg-observation-nct06973304-2026-09-08-9eb77aabedd9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06973304 at 2026-11-15T21:55:23.600Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct06973304-2026-09-08-9eb77aabedd9`](#source-ctg-observation-nct06973304-2026-09-08-9eb77aabedd9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06973304 at 2026-11-15T21:55:23.600Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was teduglutide. ([`ctg-observation-nct06973304-2026-09-08-9eb77aabedd9`](#source-ctg-observation-nct06973304-2026-09-08-9eb77aabedd9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06973304-2026-09-08-9eb77aabedd9`](#source-ctg-observation-nct06973304-2026-09-08-9eb77aabedd9))

### Sources

<a id="source-ctg-observation-nct06973304-2026-09-08-9eb77aabedd9"></a>
- **ClinicalTrials.gov record NCT06973304 · retained source version 2026-09-08:9eb77aabedd9c8da0449b48280bbe6ae9fb77fbfac5fa806cdf5b5414420264d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06973304) (`ctg-observation-nct06973304-2026-09-08-9eb77aabedd9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06973304." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#clinicaltrials-gov-nct06973304-teduglutide-v1 SHA-256: fea3feab3aec8b9642284d702c5749b40bffe4f08ca0f556f7e86abc8afc3baa.

---

<a id="fda-drugs-nda203441-v1"></a>

## Drugs@FDA application NDA203441

> The official Drugs@FDA dataset lists original submission 1 for NDA 203441 with status AP dated 2012-12-21, and names teduglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda203441:v1`
- Evidence domain: Regulatory
- Date in source: 2012-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda203441/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#fda-drugs-nda203441-v1
- Content SHA-256: `f7d554be32bff0e8493ad672e55cbe215ad32e2e2ef05b17dcc135ea845d4718`

### Claims and source pins

#### Headline

Drugs@FDA application NDA203441 ([`fda-drugs-nda203441-2012-12-21-bd6fee653155`](#source-fda-drugs-nda203441-2012-12-21-bd6fee653155))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 203441 with status AP dated 2012-12-21, and names teduglutide among the application record's active ingredients. ([`fda-drugs-nda203441-2012-12-21-bd6fee653155`](#source-fda-drugs-nda203441-2012-12-21-bd6fee653155))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 203441 with status AP dated 2012-12-21, and names teduglutide among the application record's active ingredients. ([`fda-drugs-nda203441-2012-12-21-bd6fee653155`](#source-fda-drugs-nda203441-2012-12-21-bd6fee653155))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda203441-2012-12-21-bd6fee653155`](#source-fda-drugs-nda203441-2012-12-21-bd6fee653155))

### Sources

<a id="source-fda-drugs-nda203441-2012-12-21-bd6fee653155"></a>
- **Drugs@FDA application NDA203441 · original submission status AP · 2012-12-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA203441%22&limit=1) (`fda-drugs-nda203441-2012-12-21-bd6fee653155`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA203441." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#fda-drugs-nda203441-v1 SHA-256: f7d554be32bff0e8493ad672e55cbe215ad32e2e2ef05b17dcc135ea845d4718.

---

<a id="federal-register-2012-20612-v1"></a>

## Federal Register notice 2012-20612

> The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.

- Evidence object: `story:federal-register-2012-20612:v1`
- Evidence domain: Regulatory
- Date in source: 2012-08-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-20612/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#federal-register-2012-20612-v1
- Content SHA-256: `b451806e0d45e1da6d4d08e7c7a27ce1c0fef75c460172acea58c2ffc92fad6e`

### Claims and source pins

#### Headline

Federal Register notice 2012-20612 ([`federal-register-2012-20612-39d5c85a2f4b`](#source-federal-register-2012-20612-39d5c85a2f4b))

#### Summary

The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide. ([`federal-register-2012-20612-39d5c85a2f4b`](#source-federal-register-2012-20612-39d5c85a2f4b))

#### Paragraph 1

The Federal Register published notice 2012-20612, attributed to FDA and its parent HHS department, on 2012-08-22. Its official title is “Gastrointestinal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide. ([`federal-register-2012-20612-39d5c85a2f4b`](#source-federal-register-2012-20612-39d5c85a2f4b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-20612-39d5c85a2f4b`](#source-federal-register-2012-20612-39d5c85a2f4b))

### Sources

<a id="source-federal-register-2012-20612-39d5c85a2f4b"></a>
- **Federal Register notice 2012-20612 · published 2012-08-22 · Gastrointestinal Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-08-22/pdf/2012-20612.pdf) (`federal-register-2012-20612-39d5c85a2f4b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-20612." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#federal-register-2012-20612-v1 SHA-256: b451806e0d45e1da6d4d08e7c7a27ce1c0fef75c460172acea58c2ffc92fad6e.

---

<a id="federal-register-2015-11000-v1"></a>

## Federal Register notice 2015-11000

> The Federal Register published notice 2015-11000, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.

- Evidence object: `story:federal-register-2015-11000:v1`
- Evidence domain: Regulatory
- Date in source: 2015-05-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2015-11000/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#federal-register-2015-11000-v1
- Content SHA-256: `40e740a1771a2c32e4b34a94467fd67360ad78f9599cb7bbd0f4cb76934b12ae`

### Claims and source pins

#### Headline

Federal Register notice 2015-11000 ([`federal-register-2015-11000-c6aa90b3b262`](#source-federal-register-2015-11000-c6aa90b3b262))

#### Summary

The Federal Register published notice 2015-11000, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide. ([`federal-register-2015-11000-c6aa90b3b262`](#source-federal-register-2015-11000-c6aa90b3b262))

#### Paragraph 1

The Federal Register published notice 2015-11000, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide. ([`federal-register-2015-11000-c6aa90b3b262`](#source-federal-register-2015-11000-c6aa90b3b262))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2015-11000-c6aa90b3b262`](#source-federal-register-2015-11000-c6aa90b3b262))

### Sources

<a id="source-federal-register-2015-11000-c6aa90b3b262"></a>
- **Federal Register notice 2015-11000 · published 2015-05-07 · Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11000.pdf) (`federal-register-2015-11000-c6aa90b3b262`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2015-11000." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#federal-register-2015-11000-v1 SHA-256: 40e740a1771a2c32e4b34a94467fd67360ad78f9599cb7bbd0f4cb76934b12ae.

---

<a id="federal-register-2024-16618-v1"></a>

## Federal Register notice 2024-16618

> The Federal Register published notice 2024-16618, attributed to FDA and its parent HHS department, on 2024-07-29. Its official title is “Pediatric Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.

- Evidence object: `story:federal-register-2024-16618:v1`
- Evidence domain: Regulatory
- Date in source: 2024-07-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-16618/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#federal-register-2024-16618-v1
- Content SHA-256: `e915264b1224b845aa5193c583fc68e9c88e7dd06614afff69d329c201c685a1`

### Claims and source pins

#### Headline

Federal Register notice 2024-16618 ([`federal-register-2024-16618-817c6c6dddb9`](#source-federal-register-2024-16618-817c6c6dddb9))

#### Summary

The Federal Register published notice 2024-16618, attributed to FDA and its parent HHS department, on 2024-07-29. Its official title is “Pediatric Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide. ([`federal-register-2024-16618-817c6c6dddb9`](#source-federal-register-2024-16618-817c6c6dddb9))

#### Paragraph 1

The Federal Register published notice 2024-16618, attributed to FDA and its parent HHS department, on 2024-07-29. Its official title is “Pediatric Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide. ([`federal-register-2024-16618-817c6c6dddb9`](#source-federal-register-2024-16618-817c6c6dddb9))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-16618-817c6c6dddb9`](#source-federal-register-2024-16618-817c6c6dddb9))

### Sources

<a id="source-federal-register-2024-16618-817c6c6dddb9"></a>
- **Federal Register notice 2024-16618 · published 2024-07-29 · Pediatric Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-07-29/pdf/2024-16618.pdf) (`federal-register-2024-16618-817c6c6dddb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-16618." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#federal-register-2024-16618-v1 SHA-256: e915264b1224b845aa5193c583fc68e9c88e7dd06614afff69d329c201c685a1.

---

<a id="pubmed-pmid-24871569-teduglutide-v1"></a>

## Teduglutide for the Treatment of Short Bowel Syndrome.

> PubMed lists PMID 24871569 in The Annals of pharmacotherapy as Review, Journal Article, with publication-date metadata of 2014-05-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24871569-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24871569-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-24871569-teduglutide-v1
- Content SHA-256: `2878c6f770e9cf1a2e75380e78f8a6e0dfafb74c479540829cfc530b0244f86d`

### Claims and source pins

#### Headline

Teduglutide for the Treatment of Short Bowel Syndrome. ([`pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169`](#source-pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169))

#### Summary

PubMed lists PMID 24871569 in The Annals of pharmacotherapy as Review, Journal Article, with publication-date metadata of 2014-05-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169`](#source-pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169))

#### Paragraph 1

PubMed lists PMID 24871569 in The Annals of pharmacotherapy as Review, Journal Article, with publication-date metadata of 2014-05-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169`](#source-pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169`](#source-pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169))

### Sources

<a id="source-pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169"></a>
- **Teduglutide for the Treatment of Short Bowel Syndrome. · retained source version 1:2019-11-20:current:6d7cb4834169b70b32197001d8df70a9b89dd7a5d642a0ab4f3cee67bf33e840** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24871569/) (`pubmed-observation-pmid-24871569-2019-11-20-6d7cb4834169`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide for the Treatment of Short Bowel Syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-24871569-teduglutide-v1 SHA-256: 2878c6f770e9cf1a2e75380e78f8a6e0dfafb74c479540829cfc530b0244f86d.

---

<a id="pubmed-pmid-27507402-teduglutide-v1"></a>

## Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide.

> PubMed lists PMID 27507402 in JPEN. Journal of parenteral and enteral nutrition as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-08-09 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27507402-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27507402-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-27507402-teduglutide-v1
- Content SHA-256: `fc6b24695054dad800a7050d23cfea98d38a2e4b02d7d882e6acd52d0b6aaa1b`

### Claims and source pins

#### Headline

Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. ([`pubmed-observation-pmid-27507402-2018-11-13-dd270985557e`](#source-pubmed-observation-pmid-27507402-2018-11-13-dd270985557e))

#### Summary

PubMed lists PMID 27507402 in JPEN. Journal of parenteral and enteral nutrition as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-08-09 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27507402-2018-11-13-dd270985557e`](#source-pubmed-observation-pmid-27507402-2018-11-13-dd270985557e))

#### Paragraph 1

PubMed lists PMID 27507402 in JPEN. Journal of parenteral and enteral nutrition as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-08-09 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27507402-2018-11-13-dd270985557e`](#source-pubmed-observation-pmid-27507402-2018-11-13-dd270985557e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27507402-2018-11-13-dd270985557e`](#source-pubmed-observation-pmid-27507402-2018-11-13-dd270985557e))

### Sources

<a id="source-pubmed-observation-pmid-27507402-2018-11-13-dd270985557e"></a>
- **Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. · retained source version 1:2018-11-13:current:dd270985557e2f3668d9b9b283ee94ceb6499c269b48031edf4305e46a995ae0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27507402/) (`pubmed-observation-pmid-27507402-2018-11-13-dd270985557e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-27507402-teduglutide-v1 SHA-256: fc6b24695054dad800a7050d23cfea98d38a2e4b02d7d882e6acd52d0b6aaa1b.

---

<a id="pubmed-pmid-30990222-teduglutide-v1"></a>

## Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome.

> PubMed lists PMID 30990222 in Inflammatory bowel diseases as Case Reports, Letter, with publication-date metadata of 2019-08-20 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30990222-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-05-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30990222-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-30990222-teduglutide-v1
- Content SHA-256: `843ac91fc59dcb7f98c90352414099876b883df48ba28b9457e91f51fa08ce9c`

### Claims and source pins

#### Headline

Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome. ([`pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d`](#source-pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d))

#### Summary

PubMed lists PMID 30990222 in Inflammatory bowel diseases as Case Reports, Letter, with publication-date metadata of 2019-08-20 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d`](#source-pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d))

#### Paragraph 1

PubMed lists PMID 30990222 in Inflammatory bowel diseases as Case Reports, Letter, with publication-date metadata of 2019-08-20 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d`](#source-pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d`](#source-pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d))

### Sources

<a id="source-pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d"></a>
- **Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome. · retained source version 1:2020-05-01:current:35b4b38f028dd5a6656e0505e1d982ad7c82911671430df4f693c0f54d61cfe2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30990222/) (`pubmed-observation-pmid-30990222-2020-05-01-35b4b38f028d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-30990222-teduglutide-v1 SHA-256: 843ac91fc59dcb7f98c90352414099876b883df48ba28b9457e91f51fa08ce9c.

---

<a id="pubmed-pmid-31176580-teduglutide-v1"></a>

## Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature.

> PubMed lists PMID 31176580 in Clinical colorectal cancer as Case Reports, Journal Article, Review, with publication-date metadata of 2019-03-11 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31176580-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-05-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31176580-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-31176580-teduglutide-v1
- Content SHA-256: `e6a7c382e497bc8ee50fa17807effebab6f69314b5b2d9823060015490ef0fd4`

### Claims and source pins

#### Headline

Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature. ([`pubmed-observation-pmid-31176580-2020-05-29-1003cee38624`](#source-pubmed-observation-pmid-31176580-2020-05-29-1003cee38624))

#### Summary

PubMed lists PMID 31176580 in Clinical colorectal cancer as Case Reports, Journal Article, Review, with publication-date metadata of 2019-03-11 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31176580-2020-05-29-1003cee38624`](#source-pubmed-observation-pmid-31176580-2020-05-29-1003cee38624))

#### Paragraph 1

PubMed lists PMID 31176580 in Clinical colorectal cancer as Case Reports, Journal Article, Review, with publication-date metadata of 2019-03-11 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31176580-2020-05-29-1003cee38624`](#source-pubmed-observation-pmid-31176580-2020-05-29-1003cee38624))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31176580-2020-05-29-1003cee38624`](#source-pubmed-observation-pmid-31176580-2020-05-29-1003cee38624))

### Sources

<a id="source-pubmed-observation-pmid-31176580-2020-05-29-1003cee38624"></a>
- **Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature. · retained source version 1:2020-05-29:current:1003cee386243440fb1cf4a4c9cecc6eb2250373ecaa75d54d2bf815e34bd6f1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31176580/) (`pubmed-observation-pmid-31176580-2020-05-29-1003cee38624`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-31176580-teduglutide-v1 SHA-256: e6a7c382e497bc8ee50fa17807effebab6f69314b5b2d9823060015490ef0fd4.

---

<a id="pubmed-pmid-31423614-teduglutide-v1"></a>

## Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.

> PubMed lists PMID 31423614 in JPEN. Journal of parenteral and enteral nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-08-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31423614-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31423614-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-31423614-teduglutide-v1
- Content SHA-256: `f5ac3628a404a3f189e0b36537890b60a119ec10cba7b78e45c389333edb7da9`

### Claims and source pins

#### Headline

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. ([`pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb`](#source-pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb))

#### Summary

PubMed lists PMID 31423614 in JPEN. Journal of parenteral and enteral nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-08-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb`](#source-pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb))

#### Paragraph 1

PubMed lists PMID 31423614 in JPEN. Journal of parenteral and enteral nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-08-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb`](#source-pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb`](#source-pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb))

### Sources

<a id="source-pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb"></a>
- **Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. · retained source version 1:2021-02-12:current:ee449ad3dbdbc12f708cf9392d4ddb7b48c848574ebb820eb09e931d27e70f04** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31423614/) (`pubmed-observation-pmid-31423614-2021-02-12-ee449ad3dbdb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-31423614-teduglutide-v1 SHA-256: f5ac3628a404a3f189e0b36537890b60a119ec10cba7b78e45c389333edb7da9.

---

<a id="pubmed-pmid-31522784-teduglutide-v1"></a>

## Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.

> PubMed lists PMID 31522784 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-08-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31522784-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-08-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31522784-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-31522784-teduglutide-v1
- Content SHA-256: `69c432b15164878f0a8e201f1b3a6ccb05247c536e4f4c1850ed0b4e01cc3564`

### Claims and source pins

#### Headline

Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. ([`pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a`](#source-pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a))

#### Summary

PubMed lists PMID 31522784 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-08-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a`](#source-pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a))

#### Paragraph 1

PubMed lists PMID 31522784 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-08-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a`](#source-pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a`](#source-pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a))

### Sources

<a id="source-pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a"></a>
- **Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. · retained source version 1:2021-08-16:current:f9da8571d93aa28be0a11e0ceb90df368465ad530792d58f278469435793b537** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31522784/) (`pubmed-observation-pmid-31522784-2021-08-16-f9da8571d93a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-31522784-teduglutide-v1 SHA-256: 69c432b15164878f0a8e201f1b3a6ccb05247c536e4f4c1850ed0b4e01cc3564.

---

<a id="pubmed-pmid-32088500-teduglutide-v1"></a>

## Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report.

> PubMed lists PMID 32088500 in Nutrition (Burbank, Los Angeles County, Calif.) as Case Reports, Journal Article, with publication-date metadata of 2020-01-07 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32088500-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32088500-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32088500-teduglutide-v1
- Content SHA-256: `e357f501e331469fe95a7a08f8656fb904f8a5e8a3be57620828d0c8b051627a`

### Claims and source pins

#### Headline

Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report. ([`pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f`](#source-pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f))

#### Summary

PubMed lists PMID 32088500 in Nutrition (Burbank, Los Angeles County, Calif.) as Case Reports, Journal Article, with publication-date metadata of 2020-01-07 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f`](#source-pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f))

#### Paragraph 1

PubMed lists PMID 32088500 in Nutrition (Burbank, Los Angeles County, Calif.) as Case Reports, Journal Article, with publication-date metadata of 2020-01-07 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f`](#source-pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f`](#source-pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f))

### Sources

<a id="source-pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f"></a>
- **Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report. · retained source version 1:2021-06-23:current:49c0b516625fc55e0e53a5962698ce6a4b7c0fa9ed37a3d5eb6a6e643f78a223** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32088500/) (`pubmed-observation-pmid-32088500-2021-06-23-49c0b516625f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32088500-teduglutide-v1 SHA-256: e357f501e331469fe95a7a08f8656fb904f8a5e8a3be57620828d0c8b051627a.

---

<a id="pubmed-pmid-32346219-teduglutide-v1"></a>

## Teduglutide for short bowel syndrome.

> PubMed lists PMID 32346219 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2020-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32346219-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32346219-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32346219-teduglutide-v1
- Content SHA-256: `d27b22708bbaf844dde4dc648545865229b2a2aa0e65e3d0408bd8145842cec8`

### Claims and source pins

#### Headline

Teduglutide for short bowel syndrome. ([`pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b`](#source-pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b))

#### Summary

PubMed lists PMID 32346219 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2020-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b`](#source-pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b))

#### Paragraph 1

PubMed lists PMID 32346219 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2020-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b`](#source-pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b`](#source-pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b))

### Sources

<a id="source-pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b"></a>
- **Teduglutide for short bowel syndrome. · retained source version 1:2020-09-28:current:db06e07faf6b0d422cb6fddb673ae2675d4f2b7d9d0fbb8f3f0525f2aeeffc51** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32346219/) (`pubmed-observation-pmid-32346219-2020-09-28-db06e07faf6b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide for short bowel syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32346219-teduglutide-v1 SHA-256: d27b22708bbaf844dde4dc648545865229b2a2aa0e65e3d0408bd8145842cec8.

---

<a id="pubmed-pmid-32804906-teduglutide-v1"></a>

## Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data.

> PubMed lists PMID 32804906 in Journal of pediatric gastroenterology and nutrition as Journal Article, with publication-date metadata of 2020-12 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32804906-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32804906-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32804906-teduglutide-v1
- Content SHA-256: `b2f6c98e7644c3958d7e4c41624d5c7b03818a9d0da8addbe34a9f467d79da68`

### Claims and source pins

#### Headline

Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data. ([`pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645`](#source-pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645))

#### Summary

PubMed lists PMID 32804906 in Journal of pediatric gastroenterology and nutrition as Journal Article, with publication-date metadata of 2020-12 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645`](#source-pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645))

#### Paragraph 1

PubMed lists PMID 32804906 in Journal of pediatric gastroenterology and nutrition as Journal Article, with publication-date metadata of 2020-12 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645`](#source-pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645`](#source-pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645))

### Sources

<a id="source-pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645"></a>
- **Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data. · retained source version 1:2021-05-20:current:70864f5b6645ced5b9b9df34d46176fc085246135733eb1487dca309febf16c6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32804906/) (`pubmed-observation-pmid-32804906-2021-05-20-70864f5b6645`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32804906-teduglutide-v1 SHA-256: b2f6c98e7644c3958d7e4c41624d5c7b03818a9d0da8addbe34a9f467d79da68.

---

<a id="pubmed-pmid-32829492-teduglutide-v1"></a>

## Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis.

> PubMed lists PMID 32829492 in JPEN. Journal of parenteral and enteral nutrition as Case Reports, Journal Article, with publication-date metadata of 2020-09-07 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32829492-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-07-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32829492-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32829492-teduglutide-v1
- Content SHA-256: `37409deac2ae9040cc2a46532a01a059c3dad069654caa9b8d4d5ba252164d51`

### Claims and source pins

#### Headline

Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis. ([`pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94`](#source-pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94))

#### Summary

PubMed lists PMID 32829492 in JPEN. Journal of parenteral and enteral nutrition as Case Reports, Journal Article, with publication-date metadata of 2020-09-07 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94`](#source-pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94))

#### Paragraph 1

PubMed lists PMID 32829492 in JPEN. Journal of parenteral and enteral nutrition as Case Reports, Journal Article, with publication-date metadata of 2020-09-07 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94`](#source-pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94`](#source-pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94))

### Sources

<a id="source-pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94"></a>
- **Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis. · retained source version 1:2021-07-08:current:f8aba93b5c9498e888677fdbf652416dcbf83a351c796a325199b22b3cafb30e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32829492/) (`pubmed-observation-pmid-32829492-2021-07-08-f8aba93b5c94`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-32829492-teduglutide-v1 SHA-256: 37409deac2ae9040cc2a46532a01a059c3dad069654caa9b8d4d5ba252164d51.

---

<a id="pubmed-pmid-34903028-teduglutide-v1"></a>

## Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide.

> PubMed lists PMID 34903028 in Nutricion hospitalaria as Case Reports, Journal Article, with publication-date metadata of 2022-02-09 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34903028-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-05-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34903028-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-34903028-teduglutide-v1
- Content SHA-256: `9a858eab6444bff50a8aa541c9b4aba30858e251fe1fbbad70e2312cdd3c05e6`

### Claims and source pins

#### Headline

Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide. ([`pubmed-observation-pmid-34903028-2022-05-01-04be56771535`](#source-pubmed-observation-pmid-34903028-2022-05-01-04be56771535))

#### Summary

PubMed lists PMID 34903028 in Nutricion hospitalaria as Case Reports, Journal Article, with publication-date metadata of 2022-02-09 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34903028-2022-05-01-04be56771535`](#source-pubmed-observation-pmid-34903028-2022-05-01-04be56771535))

#### Paragraph 1

PubMed lists PMID 34903028 in Nutricion hospitalaria as Case Reports, Journal Article, with publication-date metadata of 2022-02-09 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34903028-2022-05-01-04be56771535`](#source-pubmed-observation-pmid-34903028-2022-05-01-04be56771535))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34903028-2022-05-01-04be56771535`](#source-pubmed-observation-pmid-34903028-2022-05-01-04be56771535))

### Sources

<a id="source-pubmed-observation-pmid-34903028-2022-05-01-04be56771535"></a>
- **Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide. · retained source version 1:2022-05-01:current:04be567715350be281b8883e2e7abb6eb551e2d9197b601b4b7a0d7b39649bd5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34903028/) (`pubmed-observation-pmid-34903028-2022-05-01-04be56771535`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-34903028-teduglutide-v1 SHA-256: 9a858eab6444bff50a8aa541c9b4aba30858e251fe1fbbad70e2312cdd3c05e6.

---

<a id="pubmed-pmid-35654733-teduglutide-v1"></a>

## Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).

> PubMed lists PMID 35654733 in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver as Journal Article, Review, Consensus Statement, with publication-date metadata of 2022-05-31 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35654733-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35654733-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-35654733-teduglutide-v1
- Content SHA-256: `58c18ba4a4bc4481af644a6c4eb55615d0d15c878e4d45167d5d0457500a6914`

### Claims and source pins

#### Headline

Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP). ([`pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189`](#source-pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189))

#### Summary

PubMed lists PMID 35654733 in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver as Journal Article, Review, Consensus Statement, with publication-date metadata of 2022-05-31 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189`](#source-pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189))

#### Paragraph 1

PubMed lists PMID 35654733 in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver as Journal Article, Review, Consensus Statement, with publication-date metadata of 2022-05-31 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189`](#source-pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189`](#source-pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189))

### Sources

<a id="source-pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189"></a>
- **Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP). · retained source version 1:2026-01-27:current:f3eeda60c1891ba8ba1a73a0b70c05c9bd8a61d4793b4e824f0cf5ccac964d27** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35654733/) (`pubmed-observation-pmid-35654733-2026-01-27-f3eeda60c189`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-35654733-teduglutide-v1 SHA-256: 58c18ba4a4bc4481af644a6c4eb55615d0d15c878e4d45167d5d0457500a6914.

---

<a id="pubmed-pmid-36177820-teduglutide-v1"></a>

## Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.

> PubMed lists PMID 36177820 in Revista espanola de enfermedades digestivas as Case Reports, Journal Article, with publication-date metadata of 2023-06 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36177820-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36177820-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-36177820-teduglutide-v1
- Content SHA-256: `3e98ff88b6b784d86907c215fe41396d347bcb0778115a2bb286119758d82715`

### Claims and source pins

#### Headline

Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy. ([`pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633`](#source-pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633))

#### Summary

PubMed lists PMID 36177820 in Revista espanola de enfermedades digestivas as Case Reports, Journal Article, with publication-date metadata of 2023-06 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633`](#source-pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633))

#### Paragraph 1

PubMed lists PMID 36177820 in Revista espanola de enfermedades digestivas as Case Reports, Journal Article, with publication-date metadata of 2023-06 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633`](#source-pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633`](#source-pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633))

### Sources

<a id="source-pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633"></a>
- **Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy. · retained source version 1:2026-01-27:current:4946f6ff1633c8d44b646b048a5250ab5f91b20ac1376ac7842e107ef4580b9b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36177820/) (`pubmed-observation-pmid-36177820-2026-01-27-4946f6ff1633`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-36177820-teduglutide-v1 SHA-256: 3e98ff88b6b784d86907c215fe41396d347bcb0778115a2bb286119758d82715.

---

<a id="pubmed-pmid-37001195-teduglutide-v1"></a>

## Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.

> PubMed lists PMID 37001195 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, with publication-date metadata of 2023-03-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37001195-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37001195-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37001195-teduglutide-v1
- Content SHA-256: `9b3a1cd3111449fa803370620b363083256575e2502834acfea5d215a70478aa`

### Claims and source pins

#### Headline

Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure. ([`pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d`](#source-pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d))

#### Summary

PubMed lists PMID 37001195 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, with publication-date metadata of 2023-03-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d`](#source-pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d))

#### Paragraph 1

PubMed lists PMID 37001195 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, with publication-date metadata of 2023-03-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d`](#source-pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d`](#source-pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d))

### Sources

<a id="source-pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d"></a>
- **Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure. · retained source version 1:2026-01-27:current:27067eec4a7da04168534dbbb3ef16cc66453b053893ec69e14dfe4fd1444226** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37001195/) (`pubmed-observation-pmid-37001195-2026-01-27-27067eec4a7d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37001195-teduglutide-v1 SHA-256: 9b3a1cd3111449fa803370620b363083256575e2502834acfea5d215a70478aa.

---

<a id="pubmed-pmid-37270286-teduglutide-v1"></a>

## Teduglutide for the treatment of short bowel syndrome: a double-edged sword?

> PubMed lists PMID 37270286 in The American journal of clinical nutrition as Editorial, Comment, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37270286-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-06-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37270286-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37270286-teduglutide-v1
- Content SHA-256: `6e2201c2d60ab897d43371ebfed7dac0b26ecfc931b0f6b93598b3b5953a741d`

### Claims and source pins

#### Headline

Teduglutide for the treatment of short bowel syndrome: a double-edged sword? ([`pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98`](#source-pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98))

#### Summary

PubMed lists PMID 37270286 in The American journal of clinical nutrition as Editorial, Comment, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98`](#source-pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98))

#### Paragraph 1

PubMed lists PMID 37270286 in The American journal of clinical nutrition as Editorial, Comment, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98`](#source-pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98`](#source-pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98))

### Sources

<a id="source-pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98"></a>
- **Teduglutide for the treatment of short bowel syndrome: a double-edged sword? · retained source version 1:2023-06-16:current:cd0c373d9e98f378ded7b9cd90ce458726b000caefc3638219a489ef8560975f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37270286/) (`pubmed-observation-pmid-37270286-2023-06-16-cd0c373d9e98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide for the treatment of short bowel syndrome: a double-edged sword?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37270286-teduglutide-v1 SHA-256: 6e2201c2d60ab897d43371ebfed7dac0b26ecfc931b0f6b93598b3b5953a741d.

---

<a id="pubmed-pmid-37270288-teduglutide-v1"></a>

## Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.

> PubMed lists PMID 37270288 in The American journal of clinical nutrition as Journal Article, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37270288-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37270288-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37270288-teduglutide-v1
- Content SHA-256: `5de51a822f2d6f98c152b33a2509a28bb6f6a13aca0895020457c18b7d0d153d`

### Claims and source pins

#### Headline

Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring. ([`pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc`](#source-pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc))

#### Summary

PubMed lists PMID 37270288 in The American journal of clinical nutrition as Journal Article, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc`](#source-pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc))

#### Paragraph 1

PubMed lists PMID 37270288 in The American journal of clinical nutrition as Journal Article, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc`](#source-pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc`](#source-pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc))

### Sources

<a id="source-pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc"></a>
- **Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring. · retained source version 1:2026-01-27:current:3739d9c312cc5e16204ad753285f213b0641ea1f926f888637b3c889982d10ba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37270288/) (`pubmed-observation-pmid-37270288-2026-01-27-3739d9c312cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37270288-teduglutide-v1 SHA-256: 5de51a822f2d6f98c152b33a2509a28bb6f6a13aca0895020457c18b7d0d153d.

---

<a id="pubmed-pmid-37270289-teduglutide-v1"></a>

## Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.

> PubMed lists PMID 37270289 in The American journal of clinical nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37270289-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-06-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37270289-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37270289-teduglutide-v1
- Content SHA-256: `2e75e248d28c4c2997c1af8775ca4833c676f492855280f2de274567026aa007`

### Claims and source pins

#### Headline

Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome. ([`pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2`](#source-pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2))

#### Summary

PubMed lists PMID 37270289 in The American journal of clinical nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2`](#source-pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2))

#### Paragraph 1

PubMed lists PMID 37270289 in The American journal of clinical nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2`](#source-pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2`](#source-pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2))

### Sources

<a id="source-pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2"></a>
- **Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome. · retained source version 1:2023-06-16:current:fdc802a8e1c2a285a2ed58994efbb11f9afb7c23bada4dd9e5d2735bf115e369** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37270289/) (`pubmed-observation-pmid-37270289-2023-06-16-fdc802a8e1c2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37270289-teduglutide-v1 SHA-256: 2e75e248d28c4c2997c1af8775ca4833c676f492855280f2de274567026aa007.

---

<a id="pubmed-pmid-37646058-teduglutide-v1"></a>

## Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.

> PubMed lists PMID 37646058 in Advanced pharmaceutical bulletin as Journal Article, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37646058-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-08-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37646058-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37646058-teduglutide-v1
- Content SHA-256: `21d8a53e37de9d17f91f1f2a19fd87d259d0c0caea7ef9a8a3f2474dd5b484d5`

### Claims and source pins

#### Headline

Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells. ([`pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9`](#source-pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9))

#### Summary

PubMed lists PMID 37646058 in Advanced pharmaceutical bulletin as Journal Article, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9`](#source-pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9))

#### Paragraph 1

PubMed lists PMID 37646058 in Advanced pharmaceutical bulletin as Journal Article, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9`](#source-pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9`](#source-pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9))

### Sources

<a id="source-pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9"></a>
- **Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells. · retained source version 1:2023-08-31:current:5af679c7fcd958931783f4ee55092945f36abe69079c2d020db5c43b0d71f46d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37646058/) (`pubmed-observation-pmid-37646058-2023-08-31-5af679c7fcd9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-37646058-teduglutide-v1 SHA-256: 21d8a53e37de9d17f91f1f2a19fd87d259d0c0caea7ef9a8a3f2474dd5b484d5.

---

<a id="pubmed-pmid-39125394-teduglutide-v1"></a>

## Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry.

> PubMed lists PMID 39125394 in Nutrients as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39125394-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39125394-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-39125394-teduglutide-v1
- Content SHA-256: `a2927ab0885cb7b4a75f56c379f763cd227e5edba544f9d7e74a51ae65d9350b`

### Claims and source pins

#### Headline

Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. ([`pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591`](#source-pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591))

#### Summary

PubMed lists PMID 39125394 in Nutrients as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591`](#source-pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591))

#### Paragraph 1

PubMed lists PMID 39125394 in Nutrients as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591`](#source-pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591`](#source-pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591))

### Sources

<a id="source-pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591"></a>
- **Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. · retained source version 1:2025-01-30:current:88326e6f259129de1c038f1c6cf6f3498c247d7f0008f13a8801d56adc7518ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39125394/) (`pubmed-observation-pmid-39125394-2025-01-30-88326e6f2591`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-39125394-teduglutide-v1 SHA-256: a2927ab0885cb7b4a75f56c379f763cd227e5edba544f9d7e74a51ae65d9350b.

---

<a id="pubmed-pmid-39519595-teduglutide-v1"></a>

## Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals.

> PubMed lists PMID 39519595 in Nutrients as Journal Article, with publication-date metadata of 2024-11-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39519595-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-11-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39519595-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-39519595-teduglutide-v1
- Content SHA-256: `0d6a8975c6672fe5a386de0662877756c1a301eac44756e1ce16ef23f4d41bd2`

### Claims and source pins

#### Headline

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals. ([`pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467`](#source-pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467))

#### Summary

PubMed lists PMID 39519595 in Nutrients as Journal Article, with publication-date metadata of 2024-11-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467`](#source-pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467))

#### Paragraph 1

PubMed lists PMID 39519595 in Nutrients as Journal Article, with publication-date metadata of 2024-11-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467`](#source-pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467`](#source-pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467))

### Sources

<a id="source-pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467"></a>
- **Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals. · retained source version 1:2024-11-16:current:61a55d2e3467bdae573589054a6c61343fa2fa85c5e627c961a75f3d803e1add** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39519595/) (`pubmed-observation-pmid-39519595-2024-11-16-61a55d2e3467`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-39519595-teduglutide-v1 SHA-256: 0d6a8975c6672fe5a386de0662877756c1a301eac44756e1ce16ef23f4d41bd2.

---

<a id="pubmed-pmid-40086997-teduglutide-v1"></a>

## Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide.

> PubMed lists PMID 40086997 in Endocrinologia, diabetes y nutricion as Case Reports, Journal Article, Review, with publication-date metadata of 2025-03 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40086997-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40086997-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-40086997-teduglutide-v1
- Content SHA-256: `b221f20a1e7baa6cc86b6ef0e5efbc767eefaba53eb047f2b416b078331fd092`

### Claims and source pins

#### Headline

Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide. ([`pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a`](#source-pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a))

#### Summary

PubMed lists PMID 40086997 in Endocrinologia, diabetes y nutricion as Case Reports, Journal Article, Review, with publication-date metadata of 2025-03 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a`](#source-pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a))

#### Paragraph 1

PubMed lists PMID 40086997 in Endocrinologia, diabetes y nutricion as Case Reports, Journal Article, Review, with publication-date metadata of 2025-03 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a`](#source-pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a`](#source-pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a))

### Sources

<a id="source-pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a"></a>
- **Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide. · retained source version 1:2025-05-15:current:63d9e9ce139a9f6a6123ff0be47d09e3aa84f89104ba1769ad3095e0ea4cf3d3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40086997/) (`pubmed-observation-pmid-40086997-2025-05-15-63d9e9ce139a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-40086997-teduglutide-v1 SHA-256: b221f20a1e7baa6cc86b6ef0e5efbc767eefaba53eb047f2b416b078331fd092.

---

<a id="pubmed-pmid-40764045-teduglutide-v1"></a>

## Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.

> PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40764045-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-10-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40764045-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-40764045-teduglutide-v1
- Content SHA-256: `e0776c5f50109a352a9774d89f303b9f0435709ca1eb6c59c8e01c02992975b8`

### Claims and source pins

#### Headline

Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries. ([`pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a`](#source-pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a))

#### Summary

PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a`](#source-pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a))

#### Paragraph 1

PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a`](#source-pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a`](#source-pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a))

### Sources

<a id="source-pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a"></a>
- **Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries. · retained source version 1:2025-10-21:current:076ff4d0de7af0b81b248f678ac1b391229358f2692248d537dc195c948d458d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40764045/) (`pubmed-observation-pmid-40764045-2025-10-21-076ff4d0de7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-40764045-teduglutide-v1 SHA-256: e0776c5f50109a352a9774d89f303b9f0435709ca1eb6c59c8e01c02992975b8.

---

<a id="pubmed-pmid-40771220-teduglutide-v1"></a>

## Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report.

> PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40771220-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-08-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40771220-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-40771220-teduglutide-v1
- Content SHA-256: `dfc43439996ab0d836217754073f694f205abb2af51eec5e8cc9d844da992b93`

### Claims and source pins

#### Headline

Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report. ([`pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3`](#source-pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3))

#### Summary

PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3`](#source-pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3))

#### Paragraph 1

PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3`](#source-pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3`](#source-pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3))

### Sources

<a id="source-pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3"></a>
- **Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report. · retained source version 1:2025-08-09:current:efbc9b34b4e34640ff1ff94eb648b27e5642fe48d4486232a372a600c137fc2b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40771220/) (`pubmed-observation-pmid-40771220-2025-08-09-efbc9b34b4e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-40771220-teduglutide-v1 SHA-256: dfc43439996ab0d836217754073f694f205abb2af51eec5e8cc9d844da992b93.

---

<a id="pubmed-pmid-41647102-teduglutide-v1"></a>

## Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study.

> PubMed lists PMID 41647102 in Intestinal Failure (New York, N.Y.) as Journal Article, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41647102-teduglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-02-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41647102-teduglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-41647102-teduglutide-v1
- Content SHA-256: `f321eab86aabbaef192dfa5c9b37fd23f0e294996ea3e555a43e81f064f3414e`

### Claims and source pins

#### Headline

Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study. ([`pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618`](#source-pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618))

#### Summary

PubMed lists PMID 41647102 in Intestinal Failure (New York, N.Y.) as Journal Article, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618`](#source-pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618))

#### Paragraph 1

PubMed lists PMID 41647102 in Intestinal Failure (New York, N.Y.) as Journal Article, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618`](#source-pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618`](#source-pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618))

### Sources

<a id="source-pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618"></a>
- **Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study. · retained source version 1:2026-02-08:current:cf2e44e296180bda702a7653e530292bf6565236119102d738f30e71419c2f5e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41647102/) (`pubmed-observation-pmid-41647102-2026-02-08-cf2e44e29618`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teduglutide.json#pubmed-pmid-41647102-teduglutide-v1 SHA-256: f321eab86aabbaef192dfa5c9b37fd23f0e294996ea3e555a43e81f064f3414e.

